COMMENTARY

T-type channels in neuropathic pain - Villain or victim?

Norbert Weiss
Institute of Organic Chemistry and Biochemistry, Czech Academy of Sciences, Prague, Czech Republic

KEYWORDS Pain; calcium channel; T-type channel; post-translational modifications; ubiquitinylation; phosphorylation; glycosylation; sumoylation

ARTICLE HISTORY Received 29 November 2019; Accepted 2 December 2019

Neuropathic pain syndromes affect between 30 and 50% of the world population and represent a significant burden for patients, society, and healthcare systems. Many hypotheses have been formulated about the mechanisms of neuropathic pain among which elevated expression of T-type calcium channels in peripheral nociceptive nerve fibers (so-called “nociceptors”) is seen as a hallmark in several experimental pain models [1]. Nociceptors have their cell bodies in the dorsal root ganglia (DRG) and express predominantly the Ca\textsubscript{v}3.2 channel subtype whose primary function is to regulate neuronal firing and synaptic transmission at dorsal horn synapses [2]. Given these important functions in peripheral sensory neurons, aberrant expression of T-type channels in primary pain fibers comes as a pertinent cellular mechanism of neuropathic pain syndromes. How this up-regulation of T-type channels occurs at a mechanistic level has been the subject of a great deal of research in recent years and several studies pointed to a role of post-translational modification of the channel protein.

Post-translational modification refers to changes a protein may undergo after translation (cleavage and/or covalent addition of chemical moieties) and serves as a secondary level of control to fine tune its functional expression. While post-translational modification of proteins is an essential part of cellular homeostasis, it has become increasingly evident that this process is altered in pathological conditions including pain syndromes. Using a mouse model or peripheral nerve injury-induced neuropathic pain, Garcia-Caballero et al., reported a decreased ubiquitinylation of Ca\textsubscript{v}3.2 channels in primary afferent nerve fibers [3]. Biochemical analysis revealed that this effect was mediated by the up-regulation of the deubiquitinylating enzyme USP5 resulting in the accumulation of Ca\textsubscript{v}3.2 in the plasma membrane. Importantly, the authors showed that prophylactic knockdown of USP5, or prophylactic disruption of the Ca\textsubscript{v}3.2/USP5 complex, was sufficient to prevent nerve-injury-induced mechanical and thermal hyperalgesia demonstrating the causal implication of the ubiquitinylation machinery in the development of neuropathic pain in this experimental model. In yet another study using the same experimental pain model, the authors reported a decreased SUMOylation of USP5 in peripheral nociceptive nerve fibers [4]. Given that SUMOylation of USP5 negatively regulates its ability to interact with Ca\textsubscript{v}3.2, decreased SUMOylated USP5 during nerve injury would favor Ca\textsubscript{v}3.2/USP5 interaction. This would add to the already elevated level of USP5, which would enhance the deubiquitinylation of Ca\textsubscript{v}3.2 and further potentiate the expression of the channel in the plasma membrane.

Asparagine (N)-linked glycosylation is another type of post-translational modification that has been reported to potentially contribute to peripheral painful diabetic neuropathy. Several in vitro studies have documented the functional importance of N-glycosylation for Ca\textsubscript{v}3.2 channels [5–7]. Of particular relevance for painful diabetic neuropathy is the observation that surface expression of recombinant Ca\textsubscript{v}3.2 is enhanced in cells exposed to elevated glucose levels and this phenomenon requires the glycosylation of the channel at asparagines N192 and N1466. Along these lines, Orestes et al., demonstrated that in vitro removal of sialic acid moieties from complex glycan structures using neuraminidase normalized T-type currents in DRG neurons from ob/ob mice (a
transgenic model of peripheral painful diabetic neuropathy), and produced analgesia in vivo [8]. The observation that neuraminidase had no effect on T-type currents in wild-type neurons would suggest an elevated degree of sialyation during diabetes, which could have contributed to the up-regulation of CaV3.2 channels. At this stage, it is not clear whether this effect relies on the sialyation of CaV3.2 per se, or on the sialyation of other cellular components that could have influenced the expression of the channel. Furthermore, whether this alteration is due to increased activity of sialyltransferases or decreased activity of neuraminidases remains to be established.

Finally, two recent studies pointed to a role of T-type channel phosphorylation in the development of chronic pain syndromes. Our group reported that homocysteine, an intermediate product in the conversion of methionine to cysteine, enhances surface expression of CaV3.2 and contributes to the development of mechanical allodynia in a rodent model of homocysteinemia. This mechanism was attributed to the phosphorylation of CaV3.2 by PKC at serines S532, S1144, and S2188 and resulted in an enhanced recycling of the channel back to the plasma membrane. Another study reported that Cdk5-dependent phosphorylation of CaV3.2 at serines S561 and S1987 also contributes to the expression of the channel in the plasma [9]. Importantly, these authors found that Cdk5 is up-regulated following spinal nerve injury and pharmacological inhibition of Cdk5 reversed mechanical allodynia.

In conclusion, post-translational modifications potently modulate the expression of T-type channels (Figure 1) and there is increasing evidence that these regulations could have a primary role in the pathological switch from nociceptive to chronic pain conditions. Pharmacological studies have demonstrated the analgesic potential of pan T-type channel blockers in animal models of neuropathic pain and early clinical studies [10]. However, these molecules usually lack selectivity and do not discriminate between physiological and pathological pain. Therefore, targeting the regulatory pathways involved in the pathological switch of T-type channels could potentially allow for a selective modulation of chronic pain syndromes without altering their physiological functions.

Disclosure statement
No potential conflict of interest was reported by the author(s).

Funding
N.W. is supported by the Institute of Organic Chemistry and Biochemistry.

ORCID
Norbert Weiss http://orcid.org/0000-0002-0040-1109

References
[1] Bourinet E, Francois A and Laffray S. T-type calcium channels in neuropathic pain. Pain. 2016;157:S15–22.
[2] Waxman SG, Zamponi GW. Regulating excitability of peripheral afferents: emerging ion channel targets. Nat Neurosci. 2014;17:153–163.

[3] García-Caballero A, Gadotti VM, Stemkowski P, et al. The deubiquitinating enzyme USP5 modulates neuropathic and inflammatory pain by enhancing Cav3.2 channel activity. Neuron. 2014;83:1144–1158.

[4] García-Caballero A, Zhang FX, Chen L, et al. SUMOylation regulates USP5-Cav3.2 calcium channel interactions. Mol Brain. 2019;12:73.

[5] Weiss N, Black SA, Bladen C, et al. Surface expression and function of Cav3.2 T-type calcium channels are controlled by asparagine-linked glycosylation. Pflugers Arch. 2013;465:1159–1170.

[6] Lazniewska J, Rzhepetskyy Y, Zhang FX, et al. Cooperative roles of glucose and asparagine-linked glycosylation in T-type calcium channel expression. Pflugers Arch. 2016;468:1837–1851.

[7] Ondacova K, Karmazinova M, Lazniewska J, et al. Modulation of Cav3.2 T-type calcium channel permeability by asparagine-linked glycosylation. Channels (Austin). 2016;10:175–184.

[8] Orestes P, Osuru HP, McIntire WE, et al. Reversal of neuropathic pain in diabetes by targeting glycosylation of Ca(V)3.2 T-type calcium channels. Diabetes. 2013;62:3828–3838.

[9] Gomez K, Calderón-Rivera A, Sandoval A, et al. Cdk5-dependent phosphorylation of Cav3.2 T-type channels: possible role in nerve ligation-induced neuropathic allodynia and the compound action potential in primary afferent C-fibers. J Neurosci. 2020;2:283–296.

[10] Snutch TP, Zamponi GW. Recent advances in the development of T-type calcium channel blockers for pain intervention. Br J Pharmacol. 2018;2375–2383. DOI:10.1111/bph.13906